Patents by Inventor Luca Gianni

Luca Gianni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
    Publication number: 20220282337
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 8, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anton Belousov, Giampaolo Bianchini, Luca Gianni, Marlene Thomas
  • IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
    Publication number: 20220170115
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: February 17, 2022
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anton Belousov, Giampaolo Bianchini, Luca Gianni, Marlene Thomas
  • IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
    Publication number: 20220090212
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 24, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anton BELOUSOV, Giampaolo BIANCHINI, Luca GIANNI, Marlene THOMAS
  • IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
    Publication number: 20200199690
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: March 10, 2020
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anton BELOUSOV, Giampaolo Bianchini, Luca GIANNI, Marlene THOMAS
  • IDENTIFICATION OF PATIENTS IN NEED OF PD-L-1 INHIBITOR COTHERAPY
    Publication number: 20180274038
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: November 16, 2017
    Publication date: September 27, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Anton Belousov, Giampaolo BIANCHINI, Luca GIANNI, Marlene THOMAS
  • Gene expression markers for predicting response to chemotherapy
    Patent number: 9605318
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: March 28, 2017
    Assignee: Genomic Health, Inc.
    Inventors: Joffre B. Baker, Steven Shak, Luca Gianni
  • IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
    Publication number: 20160333414
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: May 22, 2015
    Publication date: November 17, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Anton BELOUSOV, Giampaolo BIANCHINI, Luca GIANNI, Marlene THOMAS
  • Gene Expression Markers for Predicting Response to Chemotherapy
    Publication number: 20110129833
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy. FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Application
    Filed: November 8, 2010
    Publication date: June 2, 2011
    Inventors: Joffre B. Baker, Steven Shak, Luca Gianni
  • Gene expression markers for predicting response to chemotherapy
    Patent number: 7871769
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: January 18, 2011
    Assignees: Genomic Health, Inc., Instituto Nazionale Tumori
    Inventors: Joffre B. Baker, Steven Shak, Luca Gianni
  • Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms
    Patent number: 7700613
    Abstract: The use of 7-ter-butoxyiminomethylcamptothecin is described in the preparation of a medicament useful for the treatment of uterine neoplasms, particularly cancer of the endometrium and of the neck of the womb.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: April 20, 2010
    Assignee: Sigma-Tau Farmaceutiche Riunite, S.p.A.
    Inventors: Paolo Carminati, Marco Corsi, Claudio Zanna, Franco Cavalli, Luca Gianni, Cristiana Sessa
  • Capecitabine Combination Therapy
    Publication number: 20090311249
    Abstract: The invention provides the use of a combination of an mTOR inhibitor and capecitabine in the treatment of cancer.
    Type: Application
    Filed: June 4, 2007
    Publication date: December 17, 2009
    Inventors: Luca Gianni, Camille L. Bedrosian
  • Use Of 7-T-Butoxyiminomethylcamptothecin For The Preparation Of A Medicament For The Treatment Of Uterine Neoplasms
    Publication number: 20080020030
    Abstract: The use of 7-ter-butoxyiminomethylcamptothecin is described in the preparation of a medicament useful for the treatment of uterine neoplasms, particularly cancer of the endometrium and of the neck of the womb.
    Type: Application
    Filed: June 8, 2005
    Publication date: January 24, 2008
    Inventors: Paolo Carminati, Marco Corsi, Claudio Zanna, Franco Cavalli, Luca Gianni, Cristiana Sessa
  • Combined use of ecteinascidin-743 and platinum antineoplastic compounds
    Publication number: 20070128201
    Abstract: ET-743 can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.
    Type: Application
    Filed: June 1, 2004
    Publication date: June 7, 2007
    Applicant: Pharma Mar, S.A.U.
    Inventors: Maurizio D'Incalci, Luca Gianni, Raffaella Giavazzi, Margarita Martin, Ian Judson, Jose Donaque, Cristiana Sessa
  • Combination therapy comprising the use of et-743 and doxorubicin for treating cancer
    Publication number: 20070082856
    Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of doxorubicin is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m2. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with doxorubicin in a dose range between 40 and 80 mg/m2.
    Type: Application
    Filed: November 12, 2004
    Publication date: April 12, 2007
    Applicant: Pharma Mar, S.A.U.
    Inventors: Luca Gianni, Maurizio D'Incalci, Filippo de Braud, Silvia Marsoni, Jose Donaque, Luis Lazaro
  • Gene expression markers for predicting response to chemotherapy
    Publication number: 20050260646
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Application
    Filed: April 7, 2005
    Publication date: November 24, 2005
    Applicant: Genomic Health Inc.
    Inventors: Joffre Baker, Steven Shak, Luca Gianni
  • Method for reducing toxicity of combined chemotherapies
    Patent number: 6927211
    Abstract: Compositions and methods are provided for use in the treatment of cancer.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: August 9, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Giorgio Minotti, Luca Gianni
  • Method for reducing toxicity of combined chemotherapies
    Patent number: 6906040
    Abstract: Compositions and methods are provided for use in the treatment of cancer.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: June 14, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Giorgio Minotti, Luca Gianni
  • Method for reducing toxicity of combined chemotherapies
    Publication number: 20040077561
    Abstract: Compositions and methods are provided for use in the treatment of cancer.
    Type: Application
    Filed: December 4, 2003
    Publication date: April 22, 2004
    Applicant: Bristol-Myers Squibb Company
    Inventors: Giorgio Minotti, Luca Gianni
  • Method for reducing toxicity of combined chemotherapies
    Publication number: 20020049170
    Abstract: Compositions and methods are provided for use in the treatment of cancer.
    Type: Application
    Filed: September 18, 2001
    Publication date: April 25, 2002
    Inventors: Giorgio Minotti, Luca Gianni
  • Method for reducing toxicity of combined chemotherapies
    Publication number: 20020049169
    Abstract: Compositions and methods are provided for use in the treatment of cancer.
    Type: Application
    Filed: September 18, 2001
    Publication date: April 25, 2002
    Inventors: Giorgio Minotti, Luca Gianni